SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 70 of 85
Word Count: 1304
Character Count: 8331

Document Content:

extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker’s bid, then that bid must then be lowered when specified purchase limits are exceeded. Other Relationships The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships with us, for which they received or will receive customary fees and expenses. Offer Restrictions Outside the United States

Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons who come into possession of this prospectus are
advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.

Selling
Restrictions

Australia

This
prospectus:

●	does
not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations
Act 2001 (Cth), or the Corporations Act;

●	has
not been, and will not be, lodged with the Australian Securities and Investments Commission,
or ASIC, as a disclosure document for the purposes of the Corporations Act and does not purport
to include the information required of a disclosure document for the purposes of the Corporations
Act; and

●	may
only be provided in Australia to select investors who are able to demonstrate that they fall
within one or more of the categories of investors, available under section 708 of the Corporations
Act, or Exempt Investors.

The
securities may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy
the securities may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any
securities may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations
Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the securities,
you represent and warrant to us that you are an Exempt Investor.

any offer of securities under this prospectus will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act,
the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure
to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the securities you undertake
to us that you will not, for a period of 12 months from the date of issue of the securities, offer, transfer, assign or otherwise alienate
those securities to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of
the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.

Canada

The
securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined
in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients,
as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the
securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable
securities laws.

Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars
of these rights or consult with a legal advisor.

Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the
disclosure requirements of NI 33-105 regarding underwriters conflicts of interest in connection with this offering.

European
Economic Area

relation to each Member State of the European Economic Area and the United Kingdom, or each a Relevant State, no securities have been
offered or will be offered pursuant to this offering to the public in that Relevant State prior to the publication of a prospectus in
relation to the securities which has been approved by the competent authority in that Relevant State or, where appropriate, approved
in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation,
except that offers of securities may be made to the public in that Relevant State at any time under the following exemptions under the
Prospectus Regulation:

any legal entity which is a qualified investor as defined under the Prospectus Regulation;

fewer than 150 natural or legal persons (other than qualified investors as defined under
the Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or

any other circumstances falling within Article 1(4) of the Prospectus Regulation,

provided
that no such offer of securities shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any
securities or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters
and us that it is a “qualified investor” within the meaning of Article 2(e) of the Prospectus Regulation. In the case of
any securities being offered to a financial intermediary as that term is used Prospectus Regulation, each such financial intermediary
will be deemed to have represented, acknowledged and agreed that the securities acquired by it in the offer have not been acquired on
a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances
which may give rise to an offer of any securities to the public other than their offer or resale in a Relevant State to qualified investors
as so defined or in circumstances in which the prior consent of the Representative has been obtained to each such proposed offer or resale.

For
the purposes of this provision, the expression an “offer to the public” in relation to securities in any Relevant State means
the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so
as to enable an investor to decide to purchase or subscribe for any securities, and the expression “Prospectus Regulation”
means Regulation (EU) 2017/1129.

Hong
Kong